Introduction
============

Breast cancer is a heterogeneous disease. Prognoses and responses to treatment of its subtypes differ based on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) status [@B1]-[@B3]. Triple-negative breast cancer (TNBC) is defined as the negativity for hormone receptors (estrogen receptor and progesterone receptor) and HER2 status, accounts for about 15-20% of breast cancer patients. Recurrence rates are particularly high within the first years; relapse risk is highest 3 years after surgery, and the risk of recurrence decreases rapidly [@B4]. TNBC is also considered a heterogeneous subtype; the prognostic role of classic pathological characteristics such as tumor size, nodal status, and tumor grade could be impaired in patients with TNBC [@B5].

Histologically, TNBC is a highly heterogeneous disease. Most patients with TNBC have invasive ductal carcinoma not otherwise specified (NOS). The remaining 10-25% of patients comprise medullary carcinoma, metaplastic carcinoma, neuroendocrine carcinoma, adenoid cystic carcinoma, invasive lobular carcinoma, apocrine carcinoma, and mixed lobular-ductal carcinoma [@B5]-[@B9]. Morphological classification of these specific histological subtypes is very important, as tumor behavior and prognosis differ between subtypes. Studies on the clinicopathological characteristics, treatment, and outcomes of the different TNBC histological subtypes are limited [@B7], [@B8]. In the present study, we used a population-based national registry (Surveillance, Epidemiology, and End Results, SEER) to investigate the clinicopathological features, treatment, and survival outcomes of TNBC patients based on their histological subtypes.

Materials and Methods
=====================

Patients
--------

Data were obtained from the current SEER dataset, which is maintained by the National Cancer Institute and consists of 18 population-based cancer registries [@B10]. Patients with female TNBC as the primary cancer were diagnosed with positive histology, and the diagnosis of specific histological subtypes required more than 100 cases. Tumors were classified based on their primary site of presentation using the International Classification of Disease for Oncology, Third Edition (ICD-O-3). Access to SEER database data did not require informed patient consent, and the Ethics Committee of Xiamen Cancer Hospital, the First Affiliated Hospital of Xiamen University, approved this study.

Demographic and clinical variables
----------------------------------

The relationship between histological subtypes and clinical characteristics, including year of diagnosis, age, race/ethnicity, tumor grade, tumor size, nodal status, distant metastatic status, and treatment was analyzed. The primary endpoints were breast cancer-specific survival (BCSS) and overall survival (OS).

Statistical Analysis
--------------------

All analyses were performed using SPSS 21.0 (SPSS Inc.). Differences between qualitative data were analyzed using the *χ*^2^ and Fisher exact probability tests. Continuous variables in patients were compared using analysis of variance. Survival curves were calculated using the Kaplan-Meier method and were compared using the log-rank test. Significant and independent risk factors of BCSS and OS were identified by Cox proportional hazard models. *p* \< 0.05 was considered statistically significant in all analyses.

Results
=======

We included 19,900 patients in the study. Table [1](#T1){ref-type="table"} shows the demographic and clinicopathological characteristics of the TNBC patients according to histological subtypes. Infiltrating ductal carcinoma NOS accounted for about 91.6% of patients (18,233), followed by metaplastic carcinoma (2.7%, 538), medullary carcinoma (1.4%, 278), mixed lobular-ductal carcinoma (1.4%, 269), lobular carcinoma NOS (1.3%, 268), apocrine adenocarcinoma (1.0%, 199), and adenoid cystic carcinoma (0.6%, 115). The median follow-up was 20 months.

Table [1](#T1){ref-type="table"} shows the patient characteristics according to histological subtypes. The mean age of lobular carcinoma NOS (65.9 years) and apocrine adenocarcinoma (66.0 years) was higher than the other subtypes (range, 53.5-62.5 years). Medullary carcinoma was more frequent in black patients (28.1%) than the other subtypes (range, 12.7-20.2%). Medullary carcinoma was also more frequently of poorly/undifferentiated (90.3%) than the other subtypes (infiltrating ductal carcinoma NOS, 79.5%; metaplastic carcinoma, 72.3%; mixed lobular-ductal carcinoma, 58.4%; apocrine adenocarcinoma, 30.7%; lobular carcinoma NOS, 26.1%; adenoid cystic carcinoma, 7.8%).

Significantly more patients with lobular carcinoma NOS, mixed lobular-ductal carcinoma, and metaplastic carcinoma had larger tumor (T3-4). There was negative lymph node involvement in 96.5% of adenoid cystic carcinomas, 78.1% of metaplastic carcinomas, 76.3% of medullary carcinomas, and 69.3% of apocrine adenocarcinomas; 46.1-62.5% of infiltrating ductal and/or lobular carcinoma was node-negative. Patients with lobular carcinoma NOS (16.0%) and mixed lobular-ductal carcinoma (10.4%) more frequently had distant stage at initial diagnosis and most did not undergo local surgery.

Figure [1](#F1){ref-type="fig"}A shows the BCSS according to histological subtypes of M0 patients who underwent local surgery (n=17,738). Mixed lobular-ductal carcinoma had the worst survival: the 3-year BCSS rate was 77.1%. The 3-year BCSS rate of infiltrating ductal carcinoma NOS, lobular carcinoma NOS, and metaplastic carcinoma was, 88.9%, 87.4%, and 81.9%, respectively. Medullary carcinoma, apocrine adenocarcinoma, and adenoid cystic carcinoma had better BCSS, where the 3-year BCSS rate was 96.6%, 97.7%, and 100%, respectively (*p* \< 0.001).

Figure [1](#F1){ref-type="fig"}B shows the OS according to histological subtypes of M0 patients who underwent local surgery. The 3-year OS rate for patients with mixed lobular-ductal carcinoma, infiltrating ductal carcinoma NOS, lobular carcinoma NOS, and metaplastic disease was 71.8%, 85.1%, 83.0%, and 76.8%, respectively. Medullary carcinoma, apocrine adenocarcinoma, and adenoid cystic carcinoma had better OS than the other subtypes: the 3-year OS rate was 94.0%, 93.0%, and 98.7%, respectively (*p* \< 0.001).

Univariate and multivariate analyses (Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, respectively) were performed on 17,738 M0 patients who underwent surgery. In univariate analysis, patients with medullary carcinoma, apocrine adenocarcinoma, and adenoid cystic carcinoma had better BCSS and OS compared to patients with infiltrating ductal carcinoma. Conversely, patients with mixed lobular-ductal carcinoma, and metaplastic carcinoma had worse BCSS and OS compared to patients with infiltrating ductal carcinoma (Table [2](#T2){ref-type="table"}).

After adjusting for age, race/ethnicity, tumor grade, tumor size, nodal status, radiotherapy, chemotherapy, and marital status in Cox regression multivariate analysis, histological subtype remained an independent prognostic factor of BCSS and OS. Compared to patients with infiltrating ductal carcinoma, patients with medullary carcinoma (BCSS, hazard ratio \[HR\] 0.327, 95% confidence interval \[CI\] 0.136-0.788, *p* = 0.013; OS, HR 0.479, 95% CI 0.257-0.893,*p* = 0.021) and apocrine adenocarcinoma (BCSS, HR 0.219, 95% CI 0.070-0.683, *p* = 0.009; OS, HR 0.486, 95% CI 0.260-0.907, *p* = 0.023) had better BCSS and OS. Conversely, patients with mixed lobular-ductal carcinoma (BCSS, HR 1.682, 95% CI 1.178-2.402, *p* = 0.004; OS, HR 1.447, 95% CI 1.045-2.004, *p* = 0.026) and metaplastic carcinoma (BCSS, HR 1.634, 95% CI 1.235-2.163, *p* = 0.001; OS, HR 1.334, 95% CI 1.043-1.706, *p* = 0.022) had worse BCSS and OS. Lobular carcinoma NOS had better OS (HR 0.660, 95% CI 0.437-0.998, *p* = 0.049) bur not BCSS than infiltrating ductal carcinoma NOS. The BCSS and OS of adenoid cystic carcinoma were not significantly different compared to survival in infiltrating ductal carcinoma (Table [3](#T3){ref-type="table"}). Age, race/ethnicity, tumor size, nodal status, radiotherapy, chemotherapy, marital status were also the independent prognostic factors of survival outcomes.

Discussion
==========

We assessed the clinicopathological characteristics and survival of TNBC according to histological subtypes using the SEER data. The histological subtypes had different clinicopathological characteristics and survival outcomes, demonstrating that TNBC can be divided into several distinct biological entities.

TNBC is a unique subtype of breast cancer with poor survival compared to other breast cancer subtypes. TNBC are histologically heterogeneous; apart from the predominant invasive ductal carcinoma, TNBC includes metaplastic, medullary, apocrine, adenoid cystic, and invasive lobular carcinomas [@B5]-[@B9]. Due to the limited number of patients with the unique TNBC subtypes, previous studies did not find prognostic differences between the TNBC histological subtypes [@B7],[@B8]. In our study, the incidence of the specific histological subtypes was similar to that of previous studies [@B7],[@B8]. Taking infiltrating ductal carcinoma as the reference, multivariate analysis showed that patients with medullary carcinoma and apocrine carcinoma had excellent prognosis and that patients with metaplastic carcinoma and mixed lobular-ductal carcinoma had poor survival outcomes; adenoid cystic carcinoma had similar survival. The specific clinicopathological and molecular characteristics of each subtype could partly explain the differing reported outcomes.

Metaplastic carcinoma is a rare heterogeneous tumor of TNBC. About 50% of metaplastic carcinoma developed local or distant metastases within 5 years after surgery [@B11]-[@B13]. Metaplastic carcinoma has larger tumors, less nodal positivity, and higher histologic grade. The survival outcomes are significantly worse than that of infiltrating ductal carcinoma [@B11],[@B14],[@B15]. Dreyer et al. (n = 28) and Montagna et al. (n = 10), who had limited patients, did not report differences in metaplastic carcinoma survival as compared with invasive ductal carcinoma [@B7],[@B8]. In this study, the clinicopathological characteristics of metaplastic carcinoma were similar to that described above, and survival was significantly poorer than that of invasive ductal carcinoma. Metaplastic carcinoma has a higher histologic grade and high Ki-67 expression [@B8],[@B11]. Lien et al. found that epithelial-mesenchymal transition-related gene markers were differentially upregulated in metaplastic carcinoma compared to invasive ductal carcinoma [@B16]. Hennessy et al. also found that the stem cell-like related markers were enriched in metaplastic carcinoma, rendering metaplastic carcinoma more likely to behave aggressively than infiltrating ductal carcinoma [@B17]. These may account for the specific disease characteristics and poor prognosis of metaplastic carcinoma.

We found that mixed lobular-ductal carcinoma had significantly worse survival outcomes compared to invasive ductal carcinoma. Patients with lobular carcinoma NOS (16.0%) and mixed lobular-ductal carcinoma (10.4%) had more distant metastases at the initial diagnosis. Dreyer et al. also showed that, in newly diagnosed patients, invasive lobular carcinoma (20%) and mixed ductal-lobular carcinoma (100%) had a higher tendency to distant metastases compared to invasive ductal carcinoma (4.2%) [@B7], which could partly explain the worse prognosis of mixed lobular-ductal carcinoma in our study. In the multivariate analyses, the OS but not BCSS of lobular carcinoma NOS was better than infiltrating ductal carcinoma NOS. There are conflicting findings on the survival outcomes between lobular carcinoma and infiltrating ductal carcinoma in previous studies [@B18]-[@B20]. The median follow-up of our study was only 20 months. Therefore, a longer follow-up time is need to confirm the survival difference between lobular carcinoma and infiltrating ductal carcinoma with TNBC.

Recurrence risk is higher in black patients and higher-grade TNBC [@B5], [@B21], [@B22]. In our study, medullary carcinoma was more frequent in black patients and of higher histologic grade. However, we found excellent prognosis for medullary carcinoma. Our results are similar to that of previous studies [@B23],[@B24]. The excellent prognosis of medullary carcinoma could be explained through gene expression profiling. Vincent-Salomon et al. showed that cytokeratin 5/6 was expressed more frequently in medullary carcinoma [@B25], for which there is better patient survival [@B26]. Moreover, Bertucci et al. reported a biological basis for the excellent prognosis of medullary carcinoma, which included effective host immune response, enhanced cancer cell apoptosis, upregulated expression of metastasis-inhibiting factors, and decreased expression of metastases-promoting factors [@B27]. In addition, medullary-like TNBC has the characteristics of prominent inflammation and anastomosing sheets, and fewer tumors with fibrotic focus features, which are associated with better prognosis [@B28].

In our study, patients with apocrine adenocarcinoma subtype were more likely to be node-negative, well/moderately differentiated, and diagnosed at older age compared to the other subtypes, which is similar to that of previous studies [@B7], [@B29]. These findings suggest that apocrine carcinoma may be less aggressive. In our study, apocrine adenocarcinoma was also a TNBC subtype with better survival. However, a previous study found that survival was similar in apocrine carcinoma and infiltrating ductal carcinoma [@B29]. An immunohistochemical study found that apocrine-type TNBC more often had p53 overexpression, lower Ki-67 expression, and epidermal growth factor receptor (EGFR) overexpression compared to non-apocrine TNBC [@B30]. However, p53 and EGFR overexpression in TNBC is associated with shorter survival [@B31]-[@B33], which does not shed light on the better survival of apocrine adenocarcinoma in our study. In our study, the better survival of apocrine adenocarcinoma as compared to infiltrating ductal carcinoma was mainly due to the presence of better clinical features, including node-negative status and well to moderate differentiation. Future studies should analyze the biological and survival differences between infiltrating ductal carcinoma and apocrine adenocarcinoma.

The Kaplan-Meier curves showed that adenoid cystic carcinoma had excellent prognosis, the 3-year BCSS and OS rates of adenoid cystic carcinoma were 100% and 98.7%, respectively. Multivariate analysis showed that survival in adenoid cystic carcinoma was not significantly different compared to that of infiltrating ductal carcinoma. The reason for these results is unclear. However, several studies have confirmed the excellent survival in adenoid cystic carcinoma [@B34], [@B35].

In this study, several limitations should be acknowledged. The first is the inherent biases in any retrospective study. However, the primary strength of the present study is that we were able to describe the epidemiology, prognostic factors, and treatment trends of these rare histological subtypes of TNBC using a SEER registry. Second, the SEER database does not include information on central pathology review, margin status, lymphovascular invasion, details of radiation therapy and chemotherapy, and local and distant recurrence data. Third, the data of radiotherapy and chemotherapy had a high specificity but the overall sensitivity was 80% and 68% in the current SEER program, respectively [@B36]. In addition, the median follow-up time was only 20 months, as the SEER database only began recording HER2 statuses in 2010.

Conclusion
==========

In conclusion, our results suggest that the unique histological subtypes of TNBC is associated with different clinicopathological characteristics and survival outcomes. Medullary carcinoma and apocrine adenocarcinoma have excellent prognosis, while mixed lobular-ductal carcinoma and metaplastic carcinoma are the most aggressive subtypes and require adjuvant systemic treatment. The histological subtypes of TNBC should be taken into consideration for tailoring treatment. Further studies are needed to confirm our results.
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BCSS

:   breast cancer-specific survival

CI

:   confidence interval

EGFR

:   epidermal growth factor receptor

HER2

:   human epidermal growth factor receptor 2

HR

:   hazard ratio

ICD-O-3

:   International Classification of Disease for Oncology, Third Edition

NOS

:   not otherwise specified

OS

:   overall survival

SEER

:   Surveillance, Epidemiology, and End Results

TNBC

:   triple-negative breast cancer.
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###### 

Patient Characteristics

  Characteristic              n           Infiltrating ductal carcinoma NOS (%)   Lobular carcinoma NOS (%)   Mixed lobular-ductal carcinoma (%)   Medullary carcinoma (%)   Metaplastic carcinoma (%)   Apocrine adenocarcinoma (%)   Adenoid cystic carcinoma (%)   *p*
  --------------------------- ----------- --------------------------------------- --------------------------- ------------------------------------ ------------------------- --------------------------- ----------------------------- ------------------------------ ----------
  n                                       18233                                   268                         269                                  278                       538                         199                           115                            
  Age (years, mean ± SD)      57.8±13.9   57.5±13.8                               65.9±13.5                   60.4±15.1                            53.5±13.2                 62.5±14.1                   66.0±12.6                     59.3±12.9                      \< 0.001
  Year of diagnosis                                                                                                                                                                                                                                                   
  2010                        4954        4511 (24.7)                             71 (26.5)                   70 (26.0)                            88 (31.7)                 124 (23.0)                  58 (29.1)                     32 (27.8)                      0.097
  2011                        5104        4652 (25.5)                             70 (26.1)                   80 (29.7)                            67 (24.1)                 153 (28.4)                  55 (27.6)                     27 (23.5)                      
  2012                        4964        4570 (25.1)                             77 (28.7)                   51 (19.0)                            66 (23.7)                 132 (24.5)                  41 (20.6)                     27 (23.5)                      
  2013                        4878        4500 (24.7)                             50 (18.7)                   68 (25.3)                            57 (20.5)                 129 (24.0)                  45 (22.6)                     29 (25.2)                      
  Race/ethnicity                                                                                                                                                                                                                                                      
  Non-hispanic white          12001       10929 (59.9)                            183 (68.3)                  179 (66.5)                           120 (43.2)                368 (68.4)                  133 (66.8)                    89 (77.4)                      \< 0.001
  Non-hispanic black          3962        3688 (20.2)                             34 (12.7)                   38 (14.1)                            78 (28.1)                 79 (14.7)                   30 (15.1)                     15 (13.0)                      
  Hispanic                    2404        2197 (12.0)                             29 (10.8)                   37 (13.8)                            64 (23.0)                 57 (10.6)                   15 (7.5)                      5 (4.3)                        
  Other and unknown           1533        1419 (7.8)                              22 (8.2)                    15 (5.6)                             16 (5.8)                  34 (6.3)                    21 (10.6)                     6 (5.2)                        
  Tumor grade                                                                                                                                                                                                                                                         
  Well differentiated         375         268 (1.5)                               19 (7.1)                    9 (3.3)                              3 (1.1)                   17 (3.2)                    11 (5.5)                      48 (41.7)                      \< 0.001
  Moderately differentiated   3307        2845 (15.6)                             144 (53.7)                  98 (36.4)                            7 (2.5)                   60 (11.2)                   119 (59.8)                    34 (29.6)                      
  Poorly/undifferentiated     15442       14505 (79.5)                            70 (26.1)                   157 (58.4)                           251 (90.3)                389 (72.3)                  61 (30.7)                     9 (7.8)                        
  Unknown                     776         615 (3.4)                               35 (13.1)                   5 (1.9)                              17 (6.1)                  72 (13.4)                   8 (4.0)                       24 (20.9)                      
  Tumor size                                                                                                                                                                                                                                                          
  T0                          22          19 (0.1)                                2 (0.7)                     0 (0)                                0 (0)                     1 (0.2)                     0 (0)                         0 (0)                          \< 0.001
  T1                          8316        7699 (42.2)                             91 (34.0)                   99 (36.8)                            119 (42.8)                124 (23.0)                  123 (61.8)                    61 (53.0)                      
  T2                          8215        7509 (41.2)                             92 (34.3)                   104 (38.7)                           142 (51.1)                264 (49.1)                  54 (27.1)                     50 (43.5)                      
  T3                          1695        1494 (8.2)                              45 (16.8)                   36 (13.4)                            10 (3.6)                  95 (17.7)                   13 (6.5)                      2 (1.7)                        
  T4                          1231        1118 (6.1)                              30 (11.2)                   20 (7.4)                             5 (1.8)                   50 (9.3)                    8 (4.0)                       0 (0)                          
  Unknown                     421         394 (2.2)                               8 (3.0)                     10 (3.7)                             2 (0.7)                   4 (0.7)                     1 (0.5)                       2 (1.7)                        
  Nodal stage                                                                                                                                                                                                                                                         
  N0                          12546       11401 (62.5)                            140 (52.2)                  124 (46.1)                           212 (76.3)                420 (78.1)                  138 (69.3)                    111 (96.5)                     \< 0.001
  N1                          4879        4574 (25.1)                             59 (22.0)                   78 (29.0)                            46 (16.5)                 80 (14.9)                   40 (20.1)                     2 (1.7)                        
  N2                          1240        1142 (6.3)                              21 (7.8)                    29 (10.8)                            13 (4.7)                  23 (4.3)                    12 (6.0)                      0 (0)                          
  N3                          992         897 (4.9)                               40 (14.9)                   31 (11.5)                            4 (1.4)                   11 (2.0)                    9 (4.5)                       0 (0)                          
  Unknown                     243         219 (1.2)                               8 (3.0)                     7 (2.6)                              3 (1.1)                   4 (0.7)                     0 (0)                         2 (1.7)                        
  Metastases status                                                                                                                                                                                                                                                   
  M0                          18811       17251 (94.6)                            225 (84.0)                  241 (89.6)                           276 (99.3)                509 (94.6)                  194 (97.5)                    115 (100)                      \< 0.001
  M1                          1089        982 (5.4)                               43 (16.0)                   28 (10.4)                            2 (0.7)                   29 (5.4)                    5 (2.5)                       0 (0)                          
  Marital status                                                                                                                                                                                                                                                      
  Single                      8159        7442 (40.8)                             126 (47.0)                  107 (39.8)                           119 (42.8)                231 (42.9)                  91 (45.7)                     43 (37.4)                      0.456
  Married                     10625       9757 (53.5)                             135 (50.4)                  147 (54.6)                           142 (51.1)                279 (51.9)                  99 (49.7)                     66 (57.4)                      
  Unknown                     1116        1034 (5.7)                              7 (2.6)                     15 (5.6)                             17 (6.1)                  28 (5.2)                    9 (4.5)                       6 (5.2)                        
  Surgery                                                                                                                                                                                                                                                             
  No                          1406        1296 (7.1)                              43 (16.0)                   28 (10.4)                            8 (2.9)                   25 (4.6)                    5 (2.5)                       1 (0.9)                        \< 0.001
  Yes                         18232       16686 (91.5)                            220 (82.1)                  237 (88.1)                           268 (96.4)                513 (95.4)                  194 (97.5)                    114 (99.1)                     
  Unknown                     262         251 (1.4)                               5 (1.9)                     4 (1.5)                              2 (0.7)                   0 (0)                       0 (0)                         0 (0)                          
  Radiotherapy                                                                                                                                                                                                                                                        
  No                          9463        8636 (47.4)                             151 (56.3)                  132 (49.1)                           125 (45.0)                278 (51.7)                  93 (46.7)                     48 (41.7)                      0.033
  Yes                         9368        8621 (47.3)                             103 (38.4)                  123 (45.7)                           130 (46.8)                234 (43.5)                  93 (46.7)                     64 (55.7)                      
  Unknown                     1069        976 (5.4)                               14 (5.2)                    14 (5.2)                             23 (8.3)                  26 (4.8)                    13 (6.5)                      3 (2.6)                        
  Chemotherapy                                                                                                                                                                                                                                                        
  No/unknown                  5402        4757(26.1)                              117(43.7)                   87 (32.3)                            62 (22.3)                 188 (34.9)                  86 (43.2)                     105 (91.3)                     \< 0.001
  Yes                         14498       13476 (73.9)                            151(56.3)                   182 (67.7)                           216 (77.7)                350 (65.1)                  113 (56.8)                    10 (8.7)                       

N, node; NOS, not otherwise specified; M, metastasis; SD, standard deviation; T, tumor.

###### 

Univariate Analysis of Prognostic Factors of BCSS and OS.

  Characteristic                    BCSS                               OS                     
  --------------------------------- -------- -------------- ---------- ------- -------------- ----------
  Age (continuous variable)         1.010    1.006-1.014    \< 0.001   1.027   1.023-1.030    \< 0.001
  Race/ethnicity                                                                              
  Non-hispanic white                1                                  1                      
  Non-hispanic black                1.287    1.120-1.478    \< 0.001   1.255   1.115-1.413    \< 0.001
  Hispanic                          0.960    0.796-1.159    0.673      0.855   0.724-1.010    0.065
  Other and unknown                 0.747    0.577-0.967    0.027      0.744   0.598-0.925    0.008
  Tumor grade                                                                                 
  Well differentiated               1                                  1                      
  Moderately differentiated         1.630    0.858-3.099    0.136      1.785   1.039-3.067    0.036
  Poorly/undifferentiated           2.551    1.368-4.757    0.003      2.47    1.459-4.182    0.001
  Tumor size                                                                                  
  T0-T1                             1                                  1                      
  T2                                2.759    2.357-3.229    \< 0.001   2.342   2.064-2.658    \< 0.001
  T3                                7.076    5.876-8.521    \< 0.001   5.229   4.468-6.120    \< 0.001
  T4                                11.667   9.553-14.249   \< 0.001   8.885   7.502-10.522   \< 0.001
  Nodal status                                                                                
  N0                                1                                  1                      
  N1                                3.108    2.697-3.581    \< 0.001   2.229   1.979-2.510    \< 0.001
  N2                                6.076    5.109-7.225    \< 0.001   4.307   3.709-5.002    \< 0.001
  N3                                11.276   9.506-13.376   \< 0.001   7.862   6.784-9.113    \< 0.001
  Radiotherapy                                                                                
  No                                1                                  1                      
  Yes                               0.851    0.768-0.942    0.002      0.751   0.688-0.821    \< 0.001
  Chemotherapy                                                                                
  No/unknown                        1                                  1                      
  Yes                               1.000    0.878-1.139    0.998      0.656   0.592-0.726    \< 0.001
  Marital status                                                                              
  Single                            1                                  1                      
  Married                           0.677    0.602-0.761    \< 0.001   0.583   0.527-0.645    \< 0.001
  Histological subtypes                                                                       
  Infiltrating duct carcinoma NOS   1                                  1                      
  Lobular carcinoma, NOS            1.315    0.826-2.096    0.249      1.271   0.849-1.903    0.244
  Mixed lobular-ductal carcinoma    2.380    1.674-3.383    \< 0.001   2.046   1.482-2.823    \< 0.001
  Medullary carcinoma               0.252    0.105-0.607    0.002      0.368   0.198-0.686    0.002
  Metaplastic carcinoma             1.798    1.371-2.358    \< 0.001   1.706   1.346-2.161    \< 0.001
  Apocrine adenocarcinoma           0.219    0.071-0.680    0.009      0.532   0.286-0.990    0.047
  Adenoid cystic carcinoma          0.125    0.018-0.891    0.038      0.183   0.046-0.730    0.016

BCSS, breast cancer-specific survival; CI, confidence interval; HR, hazard ratio; N, node; NOS, not otherwise specified; OS, overall survival; T, tumor.

###### 

Multivariate Analysis of Prognostic Factors of BCSS and OS

  ---------------------------------------------------------------------------------------------------
  Characteristic\                   BCSS                             OS                    
  --------------------------------- ------- ------------- ---------- ------- ------------- ----------
  Age (continuous variable)         1.014   1.010-1.019   \< 0.001   1.022   1.018-1.026   \< 0.001

  Race/ethnicity                                                                           

  Non-hispanic white                1                                1                     

  Non-hispanic black                1.159   1.004-1.338   0.044      1.196   1.058-1.351   0.004

  Hispanic                          0.876   0.724-1.061   0.177      0.876   0.740-1.038   0.128

  Other and unknown                 0.757   0.584-0.980   0.035      0.778   0.625-0.968   0.025

  Tumor grade                                                                              

  Well differentiated               1                                1                     

  Moderately differentiated         1.021   0.535-1.951   0.949      1.262   0.731-2.178   0.403

  Poorly/undifferentiated           1.323   0.704-2.488   0.384      1.626   0.953-2.774   0.074

  Tumor size                                                                               

  T0-T1                             1                                1                     

  T2                                2.043   1.737-2.403   \< 0.001   1.996   1.749-2.277   \< 0.001

  T3                                3.999   3.279-4.877   \< 0.001   3.784   3.194-4.484   \< 0.001

  T4                                4.745   3.819-5.896   \< 0.001   4.482   3.717-5.405   \< 0.001

  Nodal status                                                                             

  N0                                1                                1                     

  N1                                2.514   2.168-2.915   \< 0.001   2.024   1.786-2.294   \< 0.001

  N2                                4.296   3.574-5.163   \< 0.001   3.293   2.807-3.864   \< 0.001

  N3                                6.891   5.722-8.299   \< 0.001   5.308   4.516-6.239   \< 0.001

  Radiotherapy                                                                             

  No                                1                                1                     

  Yes                               0.675   0.599-0.761   \< 0.001   0.713   0.641-0.792   \< 0.001

  Chemotherapy                                                                             

  No/unknown                        ---                              1                     

  Yes                               ---     ---           ---        0.617   0.545-0.700   \< 0.001

  Marital status                                                                           

  Single                            1                                1                     

  Married                           0.844   0.747-0.953   \< 0.001   0.787   0.708-0.876   \< 0.001

  Histological subtypes                                                                    

  Infiltrating duct carcinoma NOS   1                                1                     

  Lobular carcinoma, NOS            0.768   0.476-1.238   0.278      0.660   0.437-0.998   0.049

  Mixed lobular-ductal carcinoma    1.682   1.178-2.402   0.004      1.447   1.045-2.004   0.026

  Medullary carcinoma               0.327   0.136-0.788   0.013      0.479   0.257-0.893   0.021

  Metaplastic carcinoma             1.634   1.235-2.163   0.001      1.334   1.043-1.706   0.022

  Apocrine adenocarcinoma           0.219   0.070-0.683   0.009      0.486   0.260-0.907   0.023

  Adenoid cystic carcinoma          0.300   0.042-2.162   0.232      0.299   0.074-1.213   0.091
  ---------------------------------------------------------------------------------------------------

BCSS, breast cancer-specific survival; CI, confidence interval; HR, hazard ratio; N, node; NOS, not otherwise specified; OS, overall survival; T, tumor.
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